<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03994211</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-290-105</org_study_id>
    <secondary_id>2019-000112-28</secondary_id>
    <nct_id>NCT03994211</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer</brief_title>
  <official_title>A Phase 1, Open-label, Parallel-group, Fixed-sequence Study to Investigate the Effect of the CYP3A Inducer Rifampin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of Pamiparib (BGB-290) in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-phase study in participants with advanced solid tumors. The first phase consists
      of Part A and Part B. Part A will investigate the effect of rifampin on the pharmacokinetics
      (PK) of pamiparib and Part B will investigate the effect of itraconazole in the PK of
      pamiparib. Phase 2 will allow participants continued access to pamiparib after the PK phase
      and will provide additional safety data.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 19, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Actual">October 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration vs. time curve (AUC)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent plasma clearance (CL/F)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution (Vz/F)</measure>
    <time_frame>up to 13 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse effects</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of laboratory abnormalities</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead electrocardiogram (ECG) parameters</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Assessment of the participant's general appearance, skin, thorax/lungs, cardiovascular, and abdomen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine pulse rate</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body temperature</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Arm A (core phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (core phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Extension phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pamiparib (28 day cycles)</intervention_name>
    <description>60 mg administered orally twice daily/ 28day cycles</description>
    <arm_group_label>Extension phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pamiparib 60 mg</intervention_name>
    <description>single dose of 60 mg pamiparib orally in the fasted state (at least 8 hours predose)</description>
    <arm_group_label>Arm A (core phase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pamiparib 20 mg</intervention_name>
    <description>single dose of 20 mg pamiparib orally in the fasted state (at least 8 hours predose)</description>
    <arm_group_label>Arm B (core phase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>200 mg itraconazole once a day approximately 30 minutes after completing a meal</description>
    <arm_group_label>Arm B (core phase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifampin</intervention_name>
    <description>600 mg rifampin once a day in the fasted state (at least 2 hours predose)</description>
    <arm_group_label>Arm A (core phase)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Age ≥ 18 years

          2. Histologically or cytologically confirmed advanced or metastatic solid tumors that are
             refractory or resistant to standard therapy or for which no suitable effective
             standard therapy exists.

          3. Disease that is evaluable per RECIST Version 1.1 or Prostate Cancer Working Group-3
             (PCWG-3)

          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (Appendix 2)

          5. Life expectancy ≥ 12 weeks

          6. Adequate hematologic and end-organ function

        Key Exclusion Criteria:

          1. History of hypersensitivity to rifampin, any rifamycin or any of the components of the
             rifampin capsule (Part A).

          2. History of hypersensitivity to itraconazole or any of the components of the
             itraconazole capsule (Part B).

          3. Prior treatment with a PARP inhibitor at therapeutic doses is allowed, provided that
             such treatment was not the most recent therapy (PARP inhibitor must have been
             discontinued ≥ 3 months prior to the first dose of pamiparib):

             - Participants who experienced prior severe toxicity to PARP inhibitors that in the
             opinion of the investigator precludes further treatment with PARP inhibitors should be
             excluded

          4. Diagnosis of Myelodysplastic syndrome (MDS)

          5. Active infection requiring systemic treatment

          6. Any of the following cardiovascular criteria:

               1. Cardiac chest pain, defined as moderate pain that limits instrumental activities
                  of daily living, ≤ 28 days before Day 1 of pamiparib administration

               2. Symptomatic pulmonary embolism ≤ 28 days before Day 1 of pamiparib administration

               3. Any history of acute myocardial infarction ≤ 6 months before Day 1 of pamiparib
                  administration

               4. Any history of heart failure meeting New York Heart Association Classification
                  III or IV (Appendix 5) ≤ 6 months before Day 1 of pamiparib

                  - Participants with congestive heart failure or history of heart failure should
                  be excluded from Part B (itraconazole)

               5. Any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before Day 1
                  of pamiparib administration

               6. Any history of cerebral vascular accident ≤ 6 months before Day 1 of pamiparib
                  administration

          7. Previous complete gastric resection or lap-band surgery, chronic diarrhea, active
             inflammatory gastrointestinal disease, known diverticular disease or any other
             disease-causing malabsorption syndrome

             - Gastroesophageal reflux disease under treatment with proton pump inhibitors is
             allowed

          8. Active bleeding disorder, including gastrointestinal bleeding, as evidenced by
             hematemesis, significant hemoptysis, or melena ≤ 6 months before Day 1 of pamiparib
             administration

          9. Use or anticipated need for food or drugs known to be strong or moderate CYP3A
             inhibitors or strong CYP3A inducers ≤ 14 days (or ≤ 5 half-lives if half-life is
             known) prior to Day 1 of pamiparib administration

         10. Known history of intolerance to the excipients of the pamiparib capsule

         11. Have known hereditary problems of galactose intolerance, the Lapp lactase deficiency
             or glucose-galactose malabsorption

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Andreu-Vieyra, MD</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Clinical Medicine</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Republican Clinical Hospital, Oncology Department</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital LuxMed</name>
      <address>
        <city>Warsaw</city>
        <zip>02-801</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>83101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

